ANTI-HIV ACTIVITY OF P GINGIVALIS

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者（PI）可能从另一个NIH来源获得主要资金，因此可以在其他CRISP条目中表示。所列机构为中心，不一定是研究者所在机构。全世界每天有16 000多人感染人体免疫缺陷病毒（艾滋病毒）。我们正在进行的研究表明，牙龈卟啉单胞菌可以抑制艾滋病毒的进入。本研究的目的是阐明牙龈卟啉单胞菌组分阻断HIV感染过程的机制。该提案的具体努力是纯化和表征牙龈卟啉单胞菌的抑制组分，其可能能够干扰HIV的口腔传播。我们的初步调查的目的是确定的流行和抗HIV活性的牙龈卟啉单胞菌菌株分离牙周炎网站在HIV血清阳性和HIV血清阴性的个人，检查病毒载量和17-kDa的抗HIV蛋白的相关性，和调查的影响，共同感染的HIV-1和牙龈卟啉单胞菌的病原体。从这项研究中获得的知识有望增加我们对艾滋病毒口服传播罕见性的理解，并为病毒进入过程提供新的见解。此外，对牙龈卟啉单胞菌抑制成分的研究可能会发现补充当前抗HIV药物的额外靶点。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The human immunodeficiency virus (HIV) is transmitted to over 16,000 people each day worldwide. Our ongoing studies indicate P. gingivalis can inhibit HIV entry. The purpose of this study is to elucidate the mechanism by which the P. gingivalis component blocks the course of HIV infection. The specific effort of this proposal is to purify and characterize the inhibitory component of P. gingivalis, which may be capable of interfering with the oral transmission of HIV. Our initial investigation is aimed at determination of the prevalence and the anti-HIV activity of P. gingivalis strains isolated from periodontitis sites in HIV seropositive and HIV seronegative individuals, examination of correlation of viral loads and 17-kDa anti-HIV protein, and investigation of the effect of co-infection of HIV-1 and P. gingivalis on the pathogenicities of the organisms. The knowledge gained from this study is expected to increase our understanding of the rarity of HIV oral transmission and to provide new insights into the viral entry process. Furthermore, the study of the P. gingivalis inhibitory component might lead to the discovery of an additional target to complement current anti-HIV drugs.